<html>
<head><title>
Prepared and filed by St Ives Financial
</title>
</head>
<body bgcolor="#FFFFFF">
<page>
<p align="center"><font size="2" face="serif"><b>UNITED STATES<br>
  SECURITIES AND EXCHANGE COMMISSION<br>
WASHINGTON, D.C. 20549</b></font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td><hr noshade size="1" width="25%"></td> </tr>
</table>
<p align="center"><font size="2" face="serif"><b>FORM 8-K</b></font></p>
<p align="center"><b><font size="2" face="serif">CURRENT REPORT<br>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></b></p>
<p align="center"><b><font size="2" face="serif">Date of Report (Date of earliest event reported):  July 5, 2006</font></b></p>

<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
  <tr valign="top">
    <td align="left">&nbsp;</td>
    <td align="center"><font size="3" face="serif"><b>Savient Pharmaceuticals, Inc.</b></font></td>
    <td align="right">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td colspan="3" align="left"><hr noshade size="1">
    </td>
  </tr>
  <tr valign="top">
    <td colspan="3" align="center"><font size="2" face="serif">(Exact Name of Registrant as
    Specified in Charter)</font></td>
  </tr>
  <tr valign="top">
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right">&nbsp;</td>
  </tr>
  <tr align="center" valign="top">
<td><font size="2" face="serif">Delaware</font></td>
<td width="34%"><font size="2" face="serif">0-15313</font></td>
<td width="33%"><font size="2" face="serif">13-3033811</font></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="center"><font size="2" face="serif">(State or Other Jurisdiction<br>
   of Incorporation)</font></td>
<td align="center"><font size="2" face="serif">(Commission<br>File Number)</font></td>
<td align="center"><font size="2" face="serif">(IRS Employer<br>Identification No.)</font></td>
</tr>
</table>
<br>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td align="center"><font size="2" face="serif">One Tower Center, 14th Floor</font><br><font size="2" face="serif">East Brunswick, New Jersey 08816</font></td>
</tr>
<tr valign="top">
  <td align="center"><hr noshade size="1">
    </td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">(Address of Principal Executive Offices) (Zip Code)</font></td>
</tr>
<tr valign="top">
  <td align="center">&nbsp;</td>
</tr>
<tr valign="top">
  <td align="center"><font size="2" face="serif">Registrant&#8217;s telephone
    number, including area code: (732) 418-9300</font></td>
</tr>
<tr valign="top">
  <td align="center">&nbsp;</td>
</tr>
<tr valign="top">
  <td align="center"><hr noshade size="1">
    </td>
</tr>
<tr valign="top">
  <td align="center"><font size="2" face="serif">(Former Name or Former Address,
    if Changed Since Last Report)</font></td>
</tr>
</table>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see</i> General Instruction A.2. below):</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img src="emptybox.gif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img src="emptybox.gif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img src="emptybox.gif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img src="emptybox.gif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p?"></a>
<p align="left"><font size="2" face="serif"><b>Item 5.02&nbsp;&nbsp;&nbsp;Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.</b></font></p>

<p align="left"><font size="2" face="serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
    July 5, 2006, Gina Gutzeit relinquished her role as Interim Chief Financial
    Officer of
Savient Pharmaceuticals, Inc. (the &#8220;Company&#8221;).</font></p>
<p align="left"><font size="2" face="serif" align="left">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On July 5, 2006, Brian J. Hayden was appointed Senior Vice President &#150; Chief Financial Officer &amp; Treasurer
    of the Company.</font></p>
<p align="left"><font size="2" face="serif">A copy of Mr. Hayden&#8217;s Employment Agreement and press release announcing his appointment are attached as Exhibits 10.1 and 99.1, respectively, to the Company&#8217;s Current Report on Form 8-K filed on July 11, 2006, which is incorporated herein by reference.</font></p>
<p align="left"><font size="2" face="serif"><b>Item 9.01&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits</b></font></p>
<p align="left"><font size="2" face="serif" align="left">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhibits</font></p>
<p align="left"><font size="2" face="serif">None.</font></p>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="center"><font size="2" face="serif">SIGNATURE</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>  <table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top"> <td align="left"><font size="1" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">SAVIENT PHARMACEUTICALS, INC.</font></td> </tr>
<tr valign="top">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="50%" align="left"><font size="2" face="serif">Date:  July 11, 2006</font></td>
<td align="left"><font size="2" face="serif">By: <u>/s/ Philip K. Yachmetz&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></font></td>
</tr>
<tr valign="top">
  <td align="left">&nbsp;</td>
  <td align="left"><font size="2" face="serif">Philip K. Yachmetz<br>
    Executive Vice President &amp; Chief Business
    Officer</font></td>
</tr>
</table>
<p align="center"><font face="serif" size="2"></font></p>
<hr noshade align="center" width="100%" size="2">
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "b413992_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 7126}]
{"company-data": {"conformed-name": "SAVIENT PHARMACEUTICALS INC", "cik": "0000722104", "assigned-sic": "2833", "irs-number": "133033811", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-15313", "film-number": "06956643"}, "business-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816", "phone": "7324189300"}, "mail-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816"}, "former-company": {"former-conformed-name": "BIO TECHNOLOGY GENERAL CORP", "date-changed": "19920703"}}
Prepared and filed by St Ives Financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  July 5, 2006
Savient Pharmaceuticals, Inc.
(Exact Name of Registrant as
    Specified in Charter)
Delaware
0-15313
13-3033811
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
One Tower Center, 14th Floor
East Brunswick, New Jersey 08816
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone
    number, including area code: (732) 418-9300
(Former Name or Former Address,
    if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02   Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
(b)     On
    July 5, 2006, Gina Gutzeit relinquished her role as Interim Chief Financial
    Officer of
Savient Pharmaceuticals, Inc. (the "Company").
(c)      On July 5, 2006, Brian J. Hayden was appointed Senior Vice President – Chief Financial Officer & Treasurer
    of the Company.
A copy of Mr. Hayden's Employment Agreement and press release announcing his appointment are attached as Exhibits 10.1 and 99.1, respectively, to the Company's Current Report on Form 8-K filed on July 11, 2006, which is incorporated herein by reference.
Item 9.01   Financial Statements and Exhibits
(c)      Exhibits
None.
Back to Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SAVIENT PHARMACEUTICALS, INC.
Date:  July 11, 2006
By:
/s/ Philip K. Yachmetz
Philip K. Yachmetz
Executive Vice President & Chief Business
    Officer